WO2023150260A3 - Multispecific compounds that target tem8, compositions, and methods - Google Patents

Multispecific compounds that target tem8, compositions, and methods Download PDF

Info

Publication number
WO2023150260A3
WO2023150260A3 PCT/US2023/012265 US2023012265W WO2023150260A3 WO 2023150260 A3 WO2023150260 A3 WO 2023150260A3 US 2023012265 W US2023012265 W US 2023012265W WO 2023150260 A3 WO2023150260 A3 WO 2023150260A3
Authority
WO
WIPO (PCT)
Prior art keywords
tem8
seq
amino acids
compositions
target
Prior art date
Application number
PCT/US2023/012265
Other languages
French (fr)
Other versions
WO2023150260A8 (en
WO2023150260A2 (en
Inventor
Martin FELICES
Jeffrey S. Miller
Michael F. KAMINSKI
Original Assignee
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Minnesota filed Critical Regents Of The University Of Minnesota
Publication of WO2023150260A2 publication Critical patent/WO2023150260A2/en
Publication of WO2023150260A3 publication Critical patent/WO2023150260A3/en
Publication of WO2023150260A8 publication Critical patent/WO2023150260A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A multispecific that targets TEM8 generally includes an anti-TEM8 targeting domain and an immune cell engaging domain. Generally, the anti-TEM8 targeting domain includes amino acids 277-390 of SEQ ID NO: 1, amino acids 277-389 of SEQ ID NO:2, amino acids 277-389 of SEQ ID NO:3, amino acids 277-389 of SEQ ID NO:4, amino acids 277-389 of SEQ ID NO:5, amino acids 277-515 of SEQ ID NO:25, or a TEM8-binding variant or fragment of any of the foregoing. In one or more embodiments, the compound can further include an immune cell activating domain.
PCT/US2023/012265 2022-02-03 2023-02-03 Compounds that target tem8, compositions, and methods WO2023150260A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306165P 2022-02-03 2022-02-03
US63/306,165 2022-02-03

Publications (3)

Publication Number Publication Date
WO2023150260A2 WO2023150260A2 (en) 2023-08-10
WO2023150260A3 true WO2023150260A3 (en) 2023-09-14
WO2023150260A8 WO2023150260A8 (en) 2023-11-23

Family

ID=87552814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/012265 WO2023150260A2 (en) 2022-02-03 2023-02-03 Compounds that target tem8, compositions, and methods

Country Status (1)

Country Link
WO (1) WO2023150260A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170355765A1 (en) * 2013-10-11 2017-12-14 The United Staes Of America, As Represented By The Secretary, Department Of Health And Human Service Tem8 antibodies and their use in treatment and detection of tumors
US20190367619A1 (en) * 2018-04-13 2019-12-05 Jean-Michel PERCIER Galectin-10 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170355765A1 (en) * 2013-10-11 2017-12-14 The United Staes Of America, As Represented By The Secretary, Department Of Health And Human Service Tem8 antibodies and their use in treatment and detection of tumors
US20190367619A1 (en) * 2018-04-13 2019-12-05 Jean-Michel PERCIER Galectin-10 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GenPept Protein ; ANONYMOUS : "Chain H, Fab 6F5 - Heavy Chain ", XP093091901, retrieved from NCBI *

Also Published As

Publication number Publication date
WO2023150260A8 (en) 2023-11-23
WO2023150260A2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
WO2020123887A3 (en) Novel crispr-cas systems for genome editing
EP4275702A3 (en) Cd70 combination therapy
WO2021178749A3 (en) Anti-ccr8 agents
TW200603193A (en) Coater with a large-area assembly of rotatable magnetrons
WO2022082179A3 (en) Engineered cas endonuclease variants for improved genome editing
WO2022047396A3 (en) Identification of agriculturally beneficial microbial compositions and uses thereof
MX2022012110A (en) Class ii, type ii crispr systems.
SA521420951B1 (en) Triazole Glycolate Oxidase Inhibitors
WO2004089294A3 (en) Compositions, methods and kits relating to her-2 cleavage
WO2021216738A3 (en) Compositions and methods of generating an immune response
CR20230467A (en) Small molecule inhibitors of mammalian slc6a19 function
MX2022007275A (en) Compositions of bile acids and phenylbutyrate compounds.
WO2022232016A3 (en) Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
WO2023150260A8 (en) Compounds that target tem8, compositions, and methods
ATE442465T1 (en) METHOD FOR DEPOSING METAL-FREE CARBON LAYERS
MX2020007393A (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds.
WO2003105753A3 (en) Targeted enzymes and methods of making and using targeted enzymes.
WO2020160453A8 (en) Modulators of yap1 expression
MX2022000328A (en) Methods for resisting frost on a substrate, compositions, and copolymers useful therefor.
AU2003232242A1 (en) Sputter method or device for the production of natural voltage optimized coatings
WO2024081739A3 (en) Covalent compounds and uses thereof
CA3241897A1 (en) Crosslinking antibodies
WO2022178557A3 (en) Pancreas targeted therapeutics and uses thereof
WO2023245021A3 (en) Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2023049816A3 (en) Bifunctional molecules and methods of using thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23750195

Country of ref document: EP

Kind code of ref document: A2